
Akili outlines adult ADHD data for prescription video game; Medtech startup to go public via SPAC
The digital medicine biotech Akili Interactive revealed topline results from a trial for its video game-like digital therapy EndeavorRx, also known as AKL-TO1, in adults with ADHD, with some positive results.
On Wednesday, the biotech said the game produced a statistically significant improvement in attention functioning from patients after six weeks of treatment compared to placebo. Improvements were also noted in several secondary outcomes related to assessments of ADHD-related symptoms and quality of life metrics. Akili reported no serious side effects.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.